BioCentury | Mar 19, 2007
Clinical News

Pralatrexate regulatory update

...lymphoma. Pralatrexate is a small molecule dihydrofolate reductase (DHFR) inhibitor. Oxford Regulatory Solutions Ltd. , Oxon...
BioCentury | Mar 30, 2005
Company News

Discovery Partners, Chroma drug discovery deal

...DPII and Chroma (Oxon U.K.) partnered to discover cancer compounds. Chroma will provide undisclosed cancer targets...
BioCentury | Nov 17, 2003
Company News

Celltech Group, Marconi plc deal

...MONI sold its 50% stake in Confirmant Ltd. to Oxford GlycoSciences (Abingdon, Oxon, U.K.), a wholly...
BioCentury | Sep 9, 2002
Company News

OxoN management update

OxoN Medica Inc. , South San Francisco, Calif. Business: Cardiovascular, Metabolic, Pulmonary Hired: Paul Wood as CEO and president, formerly president and CEO of Centaur Pharmaceuticals Inc. WIR Staff Cardiovascular Pulmonary...
BioCentury | Sep 3, 2002
Company News

Oxon names Wood president and CEO

...took after ELN acquired Neurex , where Wood was VP of research and preclinical development. Oxon...
Items per page:
1 - 5 of 5
BioCentury | Mar 19, 2007
Clinical News

Pralatrexate regulatory update

...lymphoma. Pralatrexate is a small molecule dihydrofolate reductase (DHFR) inhibitor. Oxford Regulatory Solutions Ltd. , Oxon...
BioCentury | Mar 30, 2005
Company News

Discovery Partners, Chroma drug discovery deal

...DPII and Chroma (Oxon U.K.) partnered to discover cancer compounds. Chroma will provide undisclosed cancer targets...
BioCentury | Nov 17, 2003
Company News

Celltech Group, Marconi plc deal

...MONI sold its 50% stake in Confirmant Ltd. to Oxford GlycoSciences (Abingdon, Oxon, U.K.), a wholly...
BioCentury | Sep 9, 2002
Company News

OxoN management update

OxoN Medica Inc. , South San Francisco, Calif. Business: Cardiovascular, Metabolic, Pulmonary Hired: Paul Wood as CEO and president, formerly president and CEO of Centaur Pharmaceuticals Inc. WIR Staff Cardiovascular Pulmonary...
BioCentury | Sep 3, 2002
Company News

Oxon names Wood president and CEO

...took after ELN acquired Neurex , where Wood was VP of research and preclinical development. Oxon...
Items per page:
1 - 5 of 5